CDC restores official U.S. immunization schedules to July 2, 2025, versions to comply with March 16 court order   

With the July 2025 schedules restored, routine ACIP recommendations are once again in effect for hepatitis A, hepatitis B (including routine birth dose), influenza, meningococcal ACWY, and rotavirus vaccines, as well as routine 2- or 3-dose HPV vaccination (depending on age at initiation). Once again, MMRV is an option on the schedule for children younger than age 4 years when preferred by parents, including VFC-eligible children.

CDC also changed its Vaccines for Children program (VFC) web pages to reflect the return to the 2025 schedule.

Clesrovimab (Enflonsia, Merck) was licensed by FDA for use as an option for RSV prevention in infants during their first RSV season in June 2025, too late to be included on the July 2 version of the 2025 schedule; however, there is no barrier to continuing its use for commercially insured or VFC-eligible infants. CDC’s VFC resolution was updated on April 20, 2026, to include clesrovimab in addition to nirsevimab (Beyfortus, Sanofi) for age-eligible infants during their first RSV season.

Readers will note that COVID-19 vaccination remains based on shared clinical decision making (SCDM) for all ages, reflecting the May 2025 HHS Secretarial Directive.

CDC indicated to its partners that it will not issue a formal communication about these changes. Immunize.org encourages clinicians, immunization program partners, and professional societies to share this information broadly and to confirm that vaccination schedules, VFC ordering guidance, patient education materials, and electronic health record prompts reflect the restored July 2, 2025, recommendations.